On June 23, 2022 EXACT Therapeutics AS ("EXACT-Tx" or "the Company", Euronext Growth: EXTX), a clinical-stage precision health company developing the Acoustic Cluster Therapy (ACT), a proprietary ultrasound-mediated drug delivery platform to enhance the efficacy of therapies across multiple diseases, reported that its collaboration partner GE Healthcare has been awarded with an innovation grant from the Norwegian Research Council (NRC) of NOK 16M to support the development of a ready-to-use formulation of Sonazoid for ultrasound imaging and therapy (Press release, Exact Therapeutics, JUN 23, 2022, View Source [SID1234616208]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The funding will support the development, the documentation and the regulatory approval of a non-lyophilised and ready-to-use liquid formulation of Sonazoid for ultrasound imaging, and regulatory approval for its use in ACT clinical trials. Academic groups Prof. Catharina de Lange Davies from the Norwegian University of Science and Technology (NTNU, long term collaborator of EXACT-Tx) and the French National Institute for Health and Medical Research (Lyon), are also involved in the collaboration.
Dr Sigrid Fossheim, Global Product Leader Ultrasound, GE Healthcare AS commented: "Removing the lyophilisation – or freeze drying – process aims to help increase manufacturing capacity for Sonazoid, and this innovation grant is a significant milestone in our ambition to grow utilization of the product."
Dr Per Walday, Chief Executive Officer, EXACT-Tx, commented: "We are very pleased with the award of this NRC grant, which brings a range of improvements and strengthens our partnership with GE Healthcare and supports an important part of the path to successful commercialisation of our PS101 product."